Anacor, partners target African sleeping sickness

A public-private-nonprofit partnership, including Palo Alto’s Anacor Pharmaceuticals Inc. , has completed early work on the first new oral drug candidate discovered specifically to combat sleeping sickness.
Anacor (NASDAQ: ANAC), Scynexis of North Carolina and the Drugs for Neglected Diseases Initiative on Tuesday published results of their preclinical studies in the journal PLos Neglected Tropical Diseases.
Phase I clinical trials in humans will start soon.